Since constitutive expression of replicative and oxidative stress biomarkers defined a subset of DE-DLBCL characterized by worse outcome and increased BCL-2 gene expression levels, we next investigated the therapeutic implications of these findings in in vitro DLBCL models, by combining different DDR inhibitors with the selective BCL-2 inhibitor Venetoclax. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.